Pacira (PCRX) BioSciences announced that it has concluded patient enrollment in Part A of its Phase 2 ASCEND study evaluating PCRX-201 for the treatment of osteoarthritis of the knee. This milestone marks the first stage of a two-part, multicenter trial designed to evaluate the safety and efficacy of PCRX-201, the company’s novel, locally administered gene therapy candidate for osteoarthritis of the knee. The company expects to report topline results from Part A of the study near the end of 2026.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCRX:
- Pacira enters exclusive license, collaboration agreement with AmacaThera
- Pacira presents updated three-year results of PCRX-201
- Pacira (PCRX) Q3 Earnings Cheat Sheet
- Pacira’s Pediatric Analgesia Study: A Potential Game-Changer for Postoperative Pain Management
- Pacira’s Innovative Study on Knee OA Pain Management: What Investors Need to Know